Electronic manufacturing services company Plexus (NASDAQ: PLXS) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q4 2026), with sales up 34.8% year on year to $1.43 billion. On top of that, next quarter’s revenue guidance ($1.44 billion at the midpoint) was surprisingly good and 5% above what analysts were expecting. Its non-GAAP profit of $2.84 per share was 11.3% above analysts’ consensus estimates.

Is now the time to buy PLXS? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Plexus’ third quarter performance surpassed Wall Street’s expectations. Management attributed the revenue and margin outperformance to robust demand across healthcare, industrial, and aerospace segments, underpinned by strong operational execution and supply chain responsiveness. CEO Todd Kelsey highlighted the company's "remarkable strength in the defense and unmanned subsectors" and pointed to new program ramps and market share gains as critical contributors.

Looking ahead, management’s guidance is driven by expectations of continued strong demand in aerospace, defense, and healthcare, alongside efficiency gains from automation and process improvements. CFO David Abuhl emphasized planned investments in people and technology to support anticipated growth, noting the company’s intent to “consistently meet and then progress through” its new margin targets. The outlook also factors in cautious assumptions around cyclical markets such as semiconductor capital equipment and commercial aerospace.

Key insights from management’s remarks

Management attributed the quarter’s growth to program ramps in key sectors, expanded customer relationships, and operational improvements that supported both revenue and margin expansion.

• Industrial sector momentum: The industrial segment, particularly semiconductor capital equipment, drove significant growth as Plexus captured new business with both existing and new clients. Management noted a 50% year-over-year increase in this subsector, citing share gains and strong collaboration with customers.
• Aerospace and defense wins: Plexus secured nearly $500 million in new manufacturing wins in aerospace and defense, with demand coming from both established defense contracts and new programs, including partnerships with emerging primes and technology entrants.
• Healthcare/life sciences expansion: The healthcare/life sciences business outpaced market growth, with strong results in therapeutics, imaging, and monitoring. Management highlighted new customer wins, including products for robotic surgery and cardiac devices, as well as increased engineering activity as a leading indicator for future growth.
• Operational efficiency gains: The company achieved improved operating margins through disciplined cost management and automation initiatives, such as the deployment of AI-driven procurement tools and enhanced manufacturing processes, leading to higher revenue per employee and machine utilization.
• Working capital and cash flow discipline: Plexus maintained record-low cash cycle days and managed working capital efficiently despite elevated investment needs, supporting free cash flow generation and return on invested capital above long-term targets.

Drivers of future performance

Plexus’ outlook is shaped by anticipated demand in core end markets, ongoing efficiency initiatives, and disciplined investment in capacity and technology.

• End market demand strength: Management expects robust revenue growth to continue, led by aerospace, defense, and industrial customers, with new program ramps and share gains in key sectors. However, they remain cautious about potential cyclical slowdowns, particularly in semiconductor capital equipment.
• Margin expansion initiatives: The company is targeting a higher non-GAAP operating margin range, supported by operational efficiency projects, automation, and process improvements. These efforts are expected to yield incremental gains, even as investments in people and technology increase.
• Disciplined capital deployment: Working capital and capital expenditure will rise to support growth, but management is focused on balancing these investments with cash flow and operating metrics. Free cash flow generation above $100 million is expected, provided operational leverage and efficiency targets are met.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will monitor (1) the pace at which new program wins ramp into revenue, especially in aerospace, defense, and healthcare; (2) sustained efficiency improvements from automation and supply chain initiatives; and (3) trends in end-market demand, particularly for semiconductor capital equipment and commercial aerospace. Progress on margin targets and capital discipline will also be critical signposts.

Plexus currently trades at $219.16, down from $239.34 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.